Biotechnology Law Report

Papers
(The median citation count of Biotechnology Law Report is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
In Juno v. Kite the Federal Circuit Strikes Down Patent Directed Towards Pioneering Innovation in CAR T-Cell Therapy3
Selected Developments in Biotechnology Law and the Biotechnology Industry3
Legal and Ethical Challenges in the Construction of China's Biobanks3
Selected Developments in Biotechnology Law and the Biotechnology Industry3
Legislative Moves on Biosecurity in China2
Patents Cannot Be Blamed for Inequitable Access to COVID-19 Vaccines2
Introduction on Biosafety Law of the People's Republic of China and Linkage Thereof with International and Domestic Regulations2
GlaxoSmithKline v. Teva: Holding a Generic Liable for an Artificial Act of Inducement2
Amgen v. Sanofi: The Supreme Court Takes up the Enablement Requirement in the Context of Therapeutic Monoclonal Antibodies1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
A Look at the Current Status of the CRISPR Patent Interferences Involving Broad Institute, University of California and University of Vienna, ToolGen, and Sigma-Aldrich1
Recent Developments at the Intersection of Pharma, Patents, and Antitrust Law1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Amgen Inc. v. Sanofi, Aventisub LLC United States Court of Appeals of the Federal Circuit, 2021 987 F.3d 10801
Recent Developments in FDA Regulatory Exclusivities1
In re Huping Hu United States Court of Appeals of the Federal Circuit, 2021 No. 2019-2104, 2021 WL 1016437 (non-precedential)1
United Therapeutics Corp. v. Liquidia Techs., Inc.1
A 2023 Review of Legislation Aimed at Increasing Generic and Biosimilar Competition1
Vectura Ltd. v. Glaxosmithkline LLC. United States Court of Appeals of the Federal Circuit, 2020 981 F.3d 10301
Navigating Cross-Border Challenges In Biobanking: Analysing Eu Legislation, ECJ Case Law, and the Role of Private International Law1
The Legislative Paradigm of China's Biosafety Law and Its Positive Significance for the SARS-CoV-2 Prevention and Control1
Observation on China's Performance in the Global Supply Chain of COVID-19 Medicine1
SawStop Holding LLC v. Vidal United States Court of Appeals of the Federal Circuit, 2022 48 F.4th 13551
In re Couvaras1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Incorrect Translation Causing a Claim to Be Indefinite Under 35 U.S.C. § 112—A Case Study of IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc.1
Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part I1
CareDx, Inc. v. Natera, Inc. United States Court of Appeals of the Federal Circuit, 2022 40 F.4th 13711
Horizon Pharma, Inc. v. Dr. Reddy's Labs. Inc. United States Court of Appeals of the Federal Circuit, 2021 No. 2019-1607, 2021 WL 48428 (Non-precedential)1
Allgenesis Biotherapeutics Inc. v. Cloudbreak Therapeutics, LLC1
Observation on the R&D Effectiveness and Application of China's Novel Coronavirus Vaccine1
Biogen MA Inc. v. EMD Serono, Inc. United States Court of Appeals of the Federal Circuit, 2020 976 F.3d 13261
Bio-Rad Labs., Inc. v. 10X Genomics Inc. United States Court of Appeals of the Federal Circuit, 2020 967 F.3d 13531
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Bayer Healthcare LLC v. Baxalta Inc. United States Court of Appeals of the Federal Circuit, 2021 989 F.3d 9641
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Regulation of Biomedical Research: Global and Indian Perspective1
The Federal Circuit Continues to Grapple with the Question of Patent Eligibility for Diagnostic Methods1
A Review of Patent Regimes on Health Biotechnology Innovation in India1
Par Pharm., Inc. v. Eagle Pharms., Inc.1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
14-Day Limit of Human Embryo Research: Moral Issues in the Patent Law in China1
Juno Therapeutics, Inc. v. Kite Pharma, Inc. United States Court of Appeals of the Federal Circuit, 202110 F.4th 13301
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Observation on the Admission Situation of the Anti-Coronavirus Drug “Remdesivir” in China1
AstraZeneca AB v. Mylan Pharms. Inc.1
Univ. of Massachusetts v. L'Oreal S.A.1
Medytox, Inc. v. Galderma S.A.1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
The Broad Institute Scores Another Victory in Its Battle with the University of California over the Patenting of CRIPSR1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Par Pharm., Inc. v. Hospira, Inc. United States Court of Appeals of the Federal Circuit, 2020 No. 2020-1273, 2020 WL 6846347 (Non-precedential)1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
XY, LLC v. Trans Ova Genetics, LC United States Court of Appeals of the Federal Circuit, 2020 968 F.3d 13231
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Moo-re Gene-edited Animals Get Regulatory Clearance: U.S. FDA Approves Genetically Engineered Cattle for Human Consumption1
Sanofi-Aventis Deutschland GmbH v. Mylan Pharms. Inc.1
Ferring B.V. v. Allergan, Inc. United States Court of Appeals of the Federal Circuit, 2020 980 F.3d 8411
Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part II1
Eli Lilly & Co. v. Apotex, Inc. United States Court of Appeals of the Federal Circuit, 2020 No. 2020-1328, 2020 WL 7490251 (Non-precedential)1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
HIPAA, HIPPA, or HIPPO: What Really Is the Heath Insurance Portability and Accountability Act?1
Novartis Pharms. Corp. v. Accord Healthcare, Inc.1
The U.S. Patent and Trademark Office Proposes New Rules Targeting Continuation Practice and Terminal Disclaimers0
Rosalind Franklin Society Proudly Announces the 2023 Award Recipient for Biotechnology Law Report0
C R Bard Inc. v. AngioDynamics, Inc. United States Court of Appeals of the Federal Circuit, 2020 979 F.3d 13720
Amgen Inc. v. Sandoz Inc. United States Court of Appeals of the Federal Circuit, 2023 No. 2022-1147, 2023 WL 29941660
The U.S. Patent and Trademark Office’s Response to Recent Developments in Artificial Intelligence0
Sanho Corp. v. Kaijet Tech. Int’l Ltd., Inc0
Genentech, Inc. v. Sandoz, Inc.0
To What Extent Does Mayo v. Prometheus Allow for the Patenting of Diagnostic Methods?0
A Feasible Pathway for Open Access to Human Embryonic Stem Cell Patents—With China's Open License for Patent as the Entry Point0
Landscape of Genome Editing Technology Patents in the European Patent Office with a Focus on CRISPR-Related Opposition Proceedings0
Recent Developments in the Listing of Patents in FDA's Orange Book0
In re Bd. of Trustees of Leland Stanford Junior Univ. United States Court of Appeals of the Federal Circuit, 2021 No. 2020-1012, 2021 WL 9227270
An Innovation Principle in Gene Technology Law?0
H. Lundbeck A/S v. Lupin Ltd.0
Jazz Pharms., Inc. v. Avadel CNS Pharms., LLC United States Court of Appeals of the Federal Circuit, 2023 No. 2023-1186, 2023 WL 21986400
Review of the UK's R&D Tax Reliefs—A Good News Story for the UK's Life Sciences Sector?0
Janssen Pharms., Inc. v. Teva Pharms. USA, Inc0
A Pharmaceutical Formulation as a Claim Term Cannot “Target” a Plasma Concentration-Time Profile Under 35 U.S.C. § 112: A Lesson from Horizon Pharma, Inc. v. Dr. Reddy's Laboratories Inc.0
Amendment of China's Biotechnology Laws in Relation to the Prevention and Containment of the COVID-19 Pandemic0
Immunex Corp. v. Sanofi-Aventis U.S. LLC United States Court of Appeals of the Federal Circuit, 202977 F.3d 12120
ChromaDex, Inc. v. Elysium Health, Inc. United States Court of Appeals of the Federal Circuit, 2023 59 F.4th 12800
Pharmaceutical Patent Term Compensation System in China—Centered on Article 42(3) of the Amendment to the Patent Law of the People's Republic of China0
Supplementary Protection Certificates in Europe: Clarity at Last?0
Minerva Surgical, Inc. v. Hologic, Inc.0
Natera, Inc. v. NeoGenomics Lab’ys, Inc0
Purdue Pharma L.P. v. Collegium Pharm., Inc0
Government Involvement in Pharmaceutical Development Can Come Back to Haunt a Drug Company0
Patentability Analysis of “Intelligent” Disease Diagnosis Methods in China in the Era of Smart Health Care0
Arbutus Biopharma Corp. v. ModernaTX, Inc. United States Court of Appeals of the Federal Circuit, 2023 65 F.4th 6560
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Cornell Rsch. Found., Inc. v. Vidal0
Dilemma and Solution of Intellectual Property Protection of Biological Genetic Resources0
Gilead Scis., Inc. v. United States0
Taiwan's Efforts to Recreate Remdesivir0
GlaxoSmithKline II and Other Recent Developments in Induced and Contributory Patent Infringement0
In re Huping Hu: Quantum Entanglement, Medical Innovation, and Patentability on the Scientific “Fringe”0
A Review of Judicial Opinions Interpreting the Novelty Provisions of the America Invents Act0
Takeda Pharm. Co. Ltd. v. Torrent Pharm. Ltd. United States Court of Appeals of the Federal Circuit, 2021 No. 2020-1552, 2021 WL 560763 (nonprecedential)0
Salix Pharms., Ltd. v. Norwich Pharms. Inc.0
Edwards Lifesciences Corp. v. Meril Life Scis. Pvt. Ltd0
Innovate, Evaluate, Legislate: U.S. Senators Forge a Path to Assess Artificial Intelligence’s Biosecurity Quandary0
Challenges in Patenting Human Stem Cell Inventions: A Comparative Perspective in USA, Europe, and India—Is India Lagging?0
A Crisis on Patenting of “Ready-to-Use” Oral Liquid Formulations: Azurity Pharms., Inc. v. Alkem Lab’ys Ltd0
Research on the Latest Progress of “Mechanism for Early Resolution of Patent Disputes” for Biological Products in China0
Novartis Pharms. Corp. v. Accord Healthcare, Inc.0
UCB, Inc. v. Actavis Lab'ys UT, Inc.0
Unproven Stem Cell Industry in the U.S.: Regulatory Challenges and Enforcement Issues0
GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc.United States Court of Appeals of the Federal Circuit, 20217 F.4th 13200
How a Dosage Regimen Patent for RRMS Treatment May Satisfy the Written Description Requirement—A Lesson from Novartis Pharmaceuticals Corp. v. Accord Healthcare, Inc.0
Generic Drugs and Innovative Drug Incentives: Early Dispute Resolution Mechanism in China0
Valeant Pharm. N. Am. LLC v. Mylan Pharm. Inc. United States Court of Appeals of the Federal Circuit, 2020 978 F.3d 13740
Univ. of S. Fla. Bd. of Trustees v. United States and the Federal Government’s Nonexclusive License under the Bayh-Dole Act0
Regulatory Landscape for Generic Drugs in India: Assessing Quality, Safety, and Efficacy Standards0
The Compulsory Licensing for Exploiting Patented COVID-19 Pharmaceutical Treatment: Legal Approaches of Some Arab Countries0
Branded Drug Companies Are Successfully Asserting the Doctrine of Equivalents in Hatch-Waxman Litigation0
The EPO Guidelines They Are a-Changin’0
Research on Intellectual Property Right Protection of Genetic Resources in China Under Benefit-Sharing0
Ethical Boundary of the Development of Human Gene Editing Technology0
Nippon Shinyaku Co. v. Sarepta Therapeutics, Inc.0
Legal Perspective of Genetically Modified Crops and Drowsy Stance of International Actors0
A 12th Year 101 Update—Diagnostic and DNA Claims Are Patent Eligible, but Pre-Mayo Patents May Continue to Fall0
Biotechnology and Intellectual Property Law: Theoretical and Practical Reflections on Albanian National Law and Jurisprudence in Comparison with EU Acquis and ECJ Case Law0
Celanese Int’l Corp. v. Int’l Trade Comm’n0
Federal Circuit Reiterates That Drug Safety and Efficacy Are Issues for the FDA, Not the Patent Laws0
Japanese CRISPR Patent and Biotech Developments in the Early Reiwa Era0
The Enablement and Written Description Requirements Through the Lens of the Federal Circuit's Actions (As Opposed to Its Words)0
Correction to: AI (Re)Defining Pharmaceutical Exclusivities, by Jonathan Kimball and Srividhya Ragavan, Biotechnol Law Rep 2022;41(1):23–29; doi: 10.1089/blr.2021.29257.sr0
The Drawing-Up of Laws on Research Involving Human Embryos in Australia: Lack of an Islamic Voice0
AI (Re)Defining Pharmaceutical Exclusivities0
Bio-Rad Lab'ys, Inc. v. Int'l Trade Comm'n0
Legal Governance of Human Gene Editing Technology: From Single Governance to Multiple Governance0
Mylan Pharms. Inc. v. Merck Sharp & Dohme Corp. United States Court of Appeals of the Federal Circuit, 2022 50 F.4th 1470
China's Challenges in Implementing Compulsory Drug Patent Licenses and its Response in the Context of COVID-190
Amarin Pharma, Inc. v. Hikma Pharms. USA, Inc.0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for Biotechnology Law Report0
The Localization of Drug Patent Linkage System in China: Where Should It Go?0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Trade Secret Protection on a Publicly Sold, Patented Spinal Implant Device: Life Spine, Inc. v. Aegis Spine, Inc.0
Interrelationship Between Genetic Resources and Traditional Knowledge: An Example from Earthworm Fibrinolytic Enzyme0
Minerva Surgical, Inc. v. Hologic, Inc. United States Court of Appeals of the Federal Circuit, 2023 59 F.4th 13710
Hologic, Inc. v. Minerva Surgical, Inc.0
ModernaTx, Inc. v. Arbutus Biopharma Corp.0
Pfizer Inc. v. Sanofi Pasteur Inc0
Regulation of Clinical Trials and Pandemic Research: Upholding Ethical Standards During a COVID-19 Crisis0
Trustees of Columbia Univ. in City of New York v. Illumina, Inc. United States Court of Appeals of the Federal Circuit, 2021 No. 2019-2302, 2021 WL 317661 (nonprecedential)0
Pac. Biosciences of California, Inc. v. Pers. Genomics Taiwan, Inc0
Glaxosmithkline LLC v. Teva Pharmaceuticals USA, Inc. United States Court of Appeals of the Federal Circuit, 2020 976 F.3d 13470
In Minerva v. Hologic, the U.S. Supreme Court Reins in the Equitable Doctrine of Assignor Estoppel0
Bracco Diagnostics Inc. v. Maia Pharm., Inc. United States Court of Appeals of the Federal Circuit, 2020 No. 2020-1387, 2020 WL 7393233 (Non-precedential)0
Baxalta Inc. v. Genentech, Inc. United States Court of Appeals of the Federal Circuit, 2020972 F.3d 13410
Janssen Ortho, LLC v. United States0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Trustees of Columbia Univ. in City of New York v. Illumina, Inc. United States Court of Appeals of the Federal Circuit, 2021 No. 2019-2302, 2021 WL 317661 (nonprecedential)0
The Fate of FTC v. Actavis, Inc. in the Biosimilar Context—Does and Should the FTC v. Actavis Decision Apply to Reverse Patent Settlements Between Brand Drug and Biosimilar Manufacturers0
China Releases Document on Ethics Review of Life Sciences: Comments and Compliance Guidelines0
Univ. of S. Fla. Bd. of Trustees v. United States0
ModernaTx, Inc. v. Arbutus Biopharma Corp.0
Pac. Biosciences of California, Inc. v. Oxford Nanopore Techs., Inc. United States Court of Appeals of the Federal Circuit, 2021 996 F.3d 1340
Tris Pharma, Inc. v. Actavis Lab'ys FL, Inc.0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Actelion Pharms. LTD v. Mylan Pharms. Inc.0
0.02717113494873